SCHEMBL5757955

SCHEMBL5757955

CNC(=O)c1cnc(N2CCC(O[Si](C)(C)C(C)(C)C)CC2)cc1-c1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SMO Q99835 12/20 0.42
TACR1 P25103 4/20 0.41
TACR3 P29371 4/20 0.41
HRH3 Q9Y5N1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759639 0.90 TACR1 (0.42) SMOTACR1TACR3
SCHEMBL5763093 0.81 HRH3 (0.40) SMOHRH3
SCHEMBL5760417 0.76 HRH3 (0.61) HRH3
SCHEMBL4672291 0.73 TACR1 (0.43) SMOTACR1
SCHEMBL6862256 0.72 CYP1A2 (0.53) TACR1
SCHEMBL6286992 0.72 PTPN11 (0.50)
SCHEMBL5757485 0.71 TACR1 (0.49) SMOTACR1TACR3
SCHEMBL14804199 0.70 ADRB1 (0.41)
SCHEMBL27567270 0.70 PAK1 (0.43)
SCHEMBL905379 0.70 CYP1A2 (0.54) TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305319-B1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-04-05 EP disclosed
US-6624176-B2 Heteroaromatic substituted amide showing antagonist activity to neurokinin 1 (NK-1, substance P) receptors for nervous system disorders and antidepressants HOFFMANN-LA ROCHE INC. 2003-09-23 US disclosed
US-20030130508-A1 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors HOFFMANN TORSTEN (DE) 2003-07-10 US disclosed
US-6576762-B2 For therapy of inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's HOFFMANN-LA ROCHE INC. 2003-06-10 US disclosed
EP-1305319-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-02 EP disclosed
US-20020038030-A1 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 US disclosed
WO-2002008232-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130508-A1 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors TACR1, NPSR1, TACR2 SMO 2815/4885TACR1 1/4885TACR3 11/4885
US-20020038030-A1 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors TACR1, NPSR1, TACR2 SMO 2815/4885TACR1 1/4885TACR3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.